IVD MEDICAL(01931): Application for stablecoin license in the United States and the official launch of the IVDNewCo Exchange ecosystem.

IVD MEDICAL (01931) announced that the company has disclosed that the group is actively building a "NewCo+RWA" Web3 exchange ecosystem ("IVDNewCo Exchange") centered around high-tech assets in medical innovation drugs (NewCo) and plans to issue a stablecoin "IVDDollar" (IVDD). This strategy aims to enhance the liquidity, financing efficiency, and accessibility of global medical innovation drug assets through the integration of Web3 technology. The group has initiated the compliance preparation for applying for a stablecoin license in the United States to support the global expansion of the ecosystem. On July 18, 2025, President Trump officially signed the "Guidelines and Establishment of the U.S. Stablecoin National Innovation Act" (referred to as the "Genius Act"). The Genius Act is the first national-level stablecoin regulatory framework in the United States, marking a significant milestone in the process of legitimizing digital assets. It is expected that the Genius Act will have a profound impact on global capital markets and the cryptocurrency industry. As an international financial center, Hong Kong published the "Stablecoin Ordinance" on May 30, 2025 (to take effect on August 1, 2025). The resonance between the Stablecoin Ordinance and U.S. policies is expected to jointly promote the accelerated development of the global stablecoin market. The board of directors happily announced the following key progress made by the group in seizing opportunities and accelerating the implementation of the previously announced group strategy: Establishment of a wholly-owned subsidiary in the United States. The company has established a wholly-owned subsidiary IVD GROUP INC. ("U.S. subsidiary") in the state of New York, USA. This U.S. subsidiary will serve as the core operating entity for the group's advancement of the IVDNewCo Exchange strategy in the United States. Formal initiation of the application for a stablecoin license in the United States. The U.S. subsidiary has formally initiated the process of submitting a stablecoin license application to U.S. regulatory agencies (including but not limited to the SEC, CFTC). This is a substantial advancement of the group's "U.S. stablecoin license application plan" as announced previously, demonstrating the group's execution and foresight in global compliance layout. Comprehensive deployment of the IVDNewCo Exchange ecosystem plan. The U.S. subsidiary will simultaneously implement the IVDNewCo Exchange ecosystem in the United States, including: Building a tokenized platform for real-world assets (RWA) based on medical innovation drug assets; Establishing regulatory financial infrastructure to support the issuance, trading, and clearing of IVDD stablecoin; Advancing the "coin-stocking linkage" mechanism with dual listing plans on Nasdaq, deepening the synergistic effects of capital markets. The group disclosed plans regarding the application for a U.S. license on the day before the signing of the Genius Act (July 17, 2025), becoming one of the very few listed companies in the Hong Kong stock market that clearly lay out a roadmap for compliance with the U.S. stablecoin ecosystem. This quick start of substantive application through the U.S. subsidiary may further consolidate the group's leading position in the "Hong Kong stablecoin concept sector." Combining the license application plan under the Hong Kong Stablecoin Ordinance and the establishment of the U.S. subsidiary, the group has built a dual financial hub compliance architecture of "Hong Kong + the United States," providing cross-regional regulatory endorsement and liquidity support for the IVDNewCo Exchange ecosystem. Leveraging the commercial network covering 1674 third-tier hospitals in China and the global acquisition capability of high-quality NewCo assets, the IVDNewCo Exchange ecosystem will become the world's first compliant trading platform focusing on medical innovation drug RWAs, attracting traditional medical capital and cryptocurrency venture capital. The acceleration of the U.S. strategy marks the entry of the group's "NewCo+RWA+Stablecoin" triple strategy into the phase of large-scale implementation. In the historical window of reshaping the global stablecoin landscape by the Genius Act, the group's dual breakthrough of "stablecoin license application + exchange ecosystem deployment" through the U.S. subsidiary is expected to deeply participate in the value allocation of the trillion-dollar compliant stablecoin market, creating a growth premium for shareholders.